NASDAQ:NVLN - Novelion Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.70
+0.30 (1.20%)
Get New Novelion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVLN

Average Price Target: $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Novelion Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.70.

N/A

The current consensus among 0 investment analysts is to n/a stock in Novelion Therapeutics. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2018Bloom BurtonDowngradeAccumulate ➝ HoldMedium
8/9/2018Royal Bank of CanadaLower Price TargetHold$6.00 ➝ $5.00Medium
5/14/2018Royal Bank of CanadaLower Price TargetSector Perform$7.00 ➝ $6.00High
3/16/2018Royal Bank of CanadaReiterated RatingHold$8.00 ➝ $7.00Low
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform$9.00 ➝ $8.00N/A
10/3/2017Royal Bank of CanadaReiterated RatingHold$9.00Low
8/8/2017Royal Bank of CanadaSet Price TargetHold$10.00 ➝ $9.00High
6/19/2017Bloom BurtonReiterated RatingAccumulateLow
2/7/2017Royal Bank of CanadaLower Price TargetSector Perform$13.50 ➝ $10.00N/A
(Data available from 6/21/2016 forward)
Novelion Therapeutics logo
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $0.70
Low: $0.70
High: $0.75

50 Day Range

MA: $0.70
Low: $0.68
High: $0.70

52 Week Range

Now: $0.70
Low: $0.54
High: $2.35

Volume

26,947 shs

Average Volume

190,529 shs

Market Capitalization

$13.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Novelion Therapeutics?

The following equities research analysts have issued stock ratings on Novelion Therapeutics in the last twelve months:
View the latest analyst ratings for NVLN.

What is the current price target for Novelion Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Novelion Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Novelion Therapeutics in the next year.
View the latest price targets for NVLN.

What is the current consensus analyst rating for Novelion Therapeutics?

Novelion Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NVLN.

What other companies compete with Novelion Therapeutics?

How do I contact Novelion Therapeutics' investor relations team?

Novelion Therapeutics' physical mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company's listed phone number is 617-500-7867 and its investor relations email address is [email protected] The official website for Novelion Therapeutics is www.novelion.com.